Program
bosmolisib
Also written as “BR101801”, “BR101801 (Phase Ia)” and “BR101801 (Phase Ib)”.
Its studies are mostly in Lymphoma, T-Cell, Peripheral · Lymphoma, Large B-Cell, Diffuse, led by Boryung Pharmaceutical.
Furthest: phase 2, since Sep 4, 20252 company-led studies, 1 open or runningNext primary completion: Sep 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boryung Pharmaceutical | 21 open or running | phase 2since Sep 4, 2025 | Jun 14, 2019 | Sep 2027phase 2 · NCT07180771 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 14, 2019First study: phase 1 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT04018248 · 26 enrolled · United States, South Korea
- Sep 4, 2025Phase 2 study in Lymphoma, T-Cell, PeripheralNCT07180771 · 44 planned
Ahead
- Sep 2027Primary completion: phase 2 study in Lymphoma, T-Cell, PeripheralNCT07180771
TargetBeta
PRKDC →read by rule
“An orally bioavailable inhibitor of phosphoinositide 3-kinase delta (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta) and DNA-dependent protein kinase (DNA-PK), ”NCIt, by rule
Other programs on PRKDC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| AMO959 | Novartis | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07180771Lymphoma, T-Cell, Peripheral | 2 | Not yet recruiting | Sep 2027 | 44 |
| NCT04018248Lymphoma, Large B-Cell, Diffuse · United States, South Korea | 1 | Completed | Sep 21, 2023 | 26 |
How it is read
Names in the registry
- “BR101801”, 1 entry
- “BR101801 (Phase Ia)”, 1 entry
- “BR101801 (Phase Ib)”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, Peripheral, 1 study
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.